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Mutation signature analysis 
identifies increased mutation 
caused by tobacco smoke 
associated DNA adducts in larynx 
squamous cell carcinoma compared 
with oral cavity and oropharynx
Andrew P. South1,2,3*, Nicoline Y. den Breems4, Tony Richa5, Uche nwagu5, Tingting Zhan3,6, 
Shiv poojan1, Ubaldo Martinez-Outschoorn3,7, Jennifer M. Johnson3,7, Adam J. Luginbuhl3,5 & 
Joseph M. curry3,5
Squamous cell carcinomas of the head and neck (HNSCC) arise from mucosal keratinocytes of the upper 
aero-digestive tract. Despite a common cell of origin and similar driver-gene mutations which divert 
cell fate from differentiation to proliferation, HNSCC are considered a heterogeneous group of tumors 
categorized by site of origin within the aero-digestive mucosa, and the presence or absence of HPV 
infection. Tobacco use is a major driver of carcinogenesis in HNSCC and is a poor prognosticator that 
has previously been associated with poor immune cell infiltration and higher mutation numbers. Here, 
we study patterns of mutations in HNSCC that are derived from the specific nucleotide changes and 
their surrounding nucleotide context (also known as mutation signatures). We identify that mutations 
linked to DNA adducts associated with tobacco smoke exposure are predominantly found in the larynx. 
Presence of this class of mutation, termed COSMIC signature 4, is responsible for the increased burden 
of mutation in this anatomical sub-site. In addition, we show that another mutation pattern, COSMIC 
signature 5, is positively associated with age in HNSCC from non-smokers and that larynx SCC from 
non-smokers have a greater number of signature 5 mutations compared with other HNSCC sub-sites. 
Immunohistochemistry demonstrates a significantly lower Ki-67 proliferation index in size matched 
larynx SCC compared with oral cavity SCC and oropharynx SCC. Collectively, these observations support 
a model where larynx SCC are characterized by slower growth and increased susceptibility to mutations 
from tobacco carcinogen DNA adducts.
Squamous cell carcinomas (SCC) arise in tissues that form a barrier between an organism and its environment 
such as the oral cavity, esophagus, upper airways of the lung, cervix, vulva, urethra and skin1. In 2017, excluding 
skin SCC for which figures are not considered, 8.8% of all new cancer cases and 11% of all cancer deaths in the US 
can be attributed to SCC2,3. With the noted exceptions of HPV vaccination, immune checkpoint inhibition and 
EGFR inhibitors, there are very limited targeted prevention or treatment strategies beyond smoking or alcohol 
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use cessation. Therefore, a better understanding of SCC initiation and progression is needed in order to develop 
effective prevention, early detection, and treatment strategies.
More than 90% of mucosal tumors of the head and neck are SCC (HNSCC) and arise at distinct anatomical 
sites such as the oral cavity, oropharynx, larynx and hypopharynx. Half of all primary HNSCC tumors will recur 
and 5 year survival is around 50–60% leading to substantive mortality figures worldwide4,5. However, overall 
survival figures differ by major anatomical sub-site and a number of studies demonstrate larynx SCC have overall 
improved 5 year survival compared with oral cavity tumors6,7, suggesting that SCC arising at different locations 
within the upper aero-digestive tract are distinct entities with respect to incidence and outcome.
HPV positive HNSCC are prevalent in the oropharynx, where a large proportion of tonsil and base of tongue 
SCC are virally driven. It is recognized that HPV infection represents a subset of HNSCC with distinct presenta-
tion, etiology and outcome5,8. Indeed, comparing all SCC from diverse anatomical sites identifies HPV positive 
tumors (principally from the head and neck and cervix) as a clear genetic subclass of SCC1. However, recent data 
does suggest that HPV infection in the larynx, hypopharynx, or oral cavity, does not change overall prognosis9,10, 
while in the oropharynx HPV has prognostic significance8, again supporting the idea that anatomical sub-site 
influences outcomes. For HPV negative tumors further sub-classification can be based on copy number altera-
tions (CNA) or presence of specific mutations and epigenetic variation11–14. Often these differences are not exclu-
sive to anatomical location where, for example, identification of NSD1 and NSD2 mutations define a sub-class of 
both oral cavity and larynx SCC11,12.
In addition to HPV, tobacco use is a primary risk factor for HNSCC and smoking status at diagnosis is associ-
ated with treatment response, risk of recurrence, and survival7,15,16. Smoking during treatment can also influence 
response17, and progression free survival decreases as a direct result of tobacco exposure at diagnosis and during 
therapy18. One prominent mechanism of carcinogenesis associated with tobacco exposure is the formation of 
DNA adducts which are compounds produced when chemicals react with DNA. Normal cellular repair pro-
cesses remove adducts and DNA is faithfully replicated when a cell divides. However, if repair processes are over-
whelmed or are deficient, the DNA adducts can persist and cause mutations during DNA replication19.
Signatures of mutation in cancer, based on collective analysis of large numbers of nucleotide changes and 
their context, can identify the underlying cause of a given cancer or group of cancers20,21. In lung carcinomas and 
HNSCC, tobacco smoke yields a distinct mutation signature dominated by C > A transversion22. The 96 nucle-
otide context of tobacco smoke associated mutations, termed COSMIC signature 4, has been validated experi-
mentally using murine tp53 mutant fibroblasts exposed to benzo[a]pyrene, a prominent tobacco carcinogen21,22. 
These data demonstrate COSMIC signature 4 is indicative of DNA adduct formation and subsequent mutation. 
Other signatures of mutation identified in HNSCC include those associated with age and natural variation in 
the genome23–25, COSMIC signatures 1 and 5, as well as endogenous deaminases of the AID (activation-induced 
cytidine deaminase) and APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide) family20,26,27. 
Because of their association with age and somatic mutation during the lifespan of an individual, signatures 1 and 
5 have been referred to as “clock-like” which could theoretically be used to predict the age of a tissue or tumor23–25. 
Indeed, serial passaging of cells in culture readily induces mutations associated with signature 528. Here we use 
mutation signature analysis to highlight distinct differences between major anatomical subsets of head and neck 
cancer and identify larynx SCC as a separate entity with regard to proliferation and mutation susceptibility.
Results
Tobacco mutation signatures associated with DNA adduct formation are significantly 
enhanced in laryngeal SCC compared with all other head and neck SCC. In our recent examina-
tion of mutation signatures in HNSCC arising in non-sun exposed sites, we observed striking sub-site specific-
ity to the presence of tobacco smoke-associated mutations (COSMIC signature 4, the signature associated with 
tobacco exposure27, Fig. 1A and Supplementary Fig. S1A). Larynx SCC have a significantly greater proportion of 
COSMIC signatures 4 and 5 compared with oral cavity and oropharynx SCC, as well as a concomitant significant 
reduction in signature 1 compared with oral cavity and oropharynx SCC, and a significant reduction in COSMIC 
signature 2 compared with oropharynx (Fig. 1A). No difference was seen in signature weight comparing oral 
cavity and oropharynx SCC. Overall, 53% of 278 TCGA (The Cancer Genome Atlas) HNSCC samples14 were 
positive for signature 4, compared with 81% of patients who reported smoking, 63% of whom were current or 
recently reformed smokers (within 15 years). When anatomical site is considered it can be seen that signature 
4 mutations were greatly enriched in the larynx (Fig. 1B) for which 82% of larynx SCC (59/72 tumors) were 
positive, while only 44% of oral cavity or oropharynx SCC were positive (90/204 tumors). The total number of 
mutations was also significantly greater in larynx compared with the major anatomical sub-site classification for 
oral cavity and oropharynx, however, this number was greatly influenced by those larynx tumors which were 
positive for tobacco-associated mutations (signature 4, Fig. 1B,C and Supplementary Fig. S1B). When HPV status 
is considered there is a statistical difference between HPV positive and HPV negative HNSCC for total muta-
tions, signature 4 and signature 5 mutations (Supplementary Fig. S2A), however this difference was dependent 
on larynx tumors where only 1 from 72 is HPV positive (Supplementary Fig. S2B,C). The number of tobac-
co-associated signature 4 mutations per tumor for those tumors that were signature 4 positive (>0 mutations 
attributed to signature 4) was significantly higher in larynx (mean 108 signature 4 mutations, n = 59) compared 
with other sub-sites (mean 15 signature 4 mutations, n = 90; oral cavity mean of 15.5 signature 4 mutations, oro-
pharynx mean of 13.1 signature 4 mutations), or HPV positive tumors (mean 9.4 signature 4 mutations, n = 12) 
(Fig. 1B and Supplementary Fig. S2). Overall, mutation burden in larynx was greater than other sub-classes of 
HNSCC and this was dependent on those larynx samples with signature 4 mutations (Fig. 1 and Supplementary 
Fig. S2). Complete signature assignation per sample is presented as both total numbers and percentage/weight in 
Supplementary Fig. S3.
3Scientific RepoRtS |         (2019) 9:19256  | https://doi.org/10.1038/s41598-019-55352-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Larynx SCC are dominated by smokers or recently reformed smokers compared with other 
sub-sites of head and neck SCC. We next compared the incidence of smoking within the TCGA HNSCC 
data set and between the three major sub-sites of HNSCC: larynx, oral cavity and oropharynx (only 2 hypophar-
ynx samples are included and so were not analyzed). As might be expected, larynx SCC, where more signature 
4 mutations are present, had a greater proportion of current smokers or recently reformed smokers compared 
with oral cavity and oropharynx (p < 0.001, Fig. 2A). Over 80% of larynx samples were from current and recently 
reformed smokers while this figure was 53% and 58% for oral cavity and oropharynx. Interestingly, while there 
were more mutations in current and recently reformed smokers across all HNSCC, the overall difference between 
mutation numbers was not as prominent when comparing sub-site mutation number differences, where larynx 
stands out as having many more overall mutations (Fig. 2B cf. Fig. 1B). The increase in smokers in the larynx SCC 
cohort might explain the increase in number of signature 4 positive tumors in larynx SCC compared with all 
other sub-sites but does not account for the increased number of signature 4 mutations per tumor. Comparison 
of pack years smoked by current and recently reformed smokers showed more pack years in larynx (mean 62 cf. 
51 in all other HNSCC) but this was not statistically significant.
Signature 5 and signature 4 mutations correlate with smoking status. In line with previous anal-
ysis22, only mutations associated with signature 4 (tobacco) and signature 5 (of unknown etiology and previously 
associated with age in a number of different cancers) showed a relationship with smoking history; current smok-
ers and recently reformed smokers have greater numbers of signature 4 and signature 5 mutations (Fig. 2C). 
Signature 5 mutation numbers also showed a stepwise reduction from historically reformed smokers (>15 years) 
and life-long never smokers suggesting a more direct relationship between signature 5 and smoking in HNSCC 
compared with signature 4 (Fig. 2C).
Signature 5 correlates with age in HNSCC non-smokers. Previous analysis has demonstrated an asso-
ciation with age and the number of signature 1 mutations in all HNSCC23 (Supplementary Fig. S4). We recently 
Figure 1. COSMIC signature 4 contributes to significantly higher mutation burden in larynx compared 
with oral cavity and oropharynx SCC. (A) Pie charts show the proportion of all single nucleotide mutations 
attributed to each of the six COSMIC mutation signatures identified in head and neck SCC for each of the 
three major sub-sites. n = total number of individual tumors for each sub-site. Signatures 1, 2, 4, 5, 13, and 18, 
are derived from version 2 of COSMIC mutational signatures. Signatures 1 and 5 are of unknown etiology and 
associated with age, signature 2 and 13 are associated with APOBEC mutagenesis, signature 4 is associated 
with tobacco smoke exposure, and signature 18 is associated reactive oxygen species. Matrix to the right of 
pie charts shows statistical significance of individual COSMIC signature weight (normalized to mutation 
number) comparing larynx with oral cavity and oropharynx tumors. No significance was seen comparing 
signature weight between oral cavity and oropharynx tumors for any of the six signatures. n.s. = no significance. 
(B) Box and whisker graphs show total number of single nucleotide mutations as well as those attributed to 
signature 4 and signature 5, identified in each of the major sub-sites of HNSCC. (C) Total mutations stratified 
by the presence (positive) or absence (negative) of signature 4 mutations. x = mean. *p < 0.05, **p < 0.01, 
***p < 0.001.
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Figure 2. Larynx SCC patients are dominated by smokers or recently reformed smokers and SCC from 
smokers have significantly more signature 4 and signature 5 mutations compared with non-smokers. Percentage 
of patients stratified by major anatomical sub-site who are either current smokers, recently reformed smokers 
(within 15 years), historically reformed smokers (for more than 15 years), or never smokers (A). Box and 
whisker plots show total mutations (B) and mutations attributed to individual signatures in HNSCC stratified 
by smoking status (C). Signatures 1, 2, 4, 5, 13, and 18, are derived from version 2 of COSMIC mutational 
signatures. Signatures 1 and 5 are of unknown etiology and associated with age, signature 2 and 13 are 
associated with APOBEC mutagenesis, signature 4 is associated with tobacco smoke exposure, and signature 18 
is associated reactive oxygen species. x = mean. *p < 0.05, **p < 0.01, ***p < 0.001.
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showed that tissue-damage associated SCC arising in the skin of patients with the rare blistering disease, recessive 
dystrophic epidermolysis bullosa (RDEB), show remarkable similarity to HNSCC at the level of mutation signa-
ture and transcriptomic analysis, and also show a correlation with age and mutation signature 5 numbers27. Given 
the similarities between RDEB SCC and HNSCC as well as the direct relationship with smoking and signature 5 
mutation numbers in HNSCC, we surmised that current or recently reformed smoking status obscures any rela-
tionship with age and signature 5 in HNSCC. Indeed, when only lifelong non-smokers or historically reformed 
smokers are analyzed it can be seen that a significant, positive correlation exists between signature 5 and age 
(Fig. 3A).
Larynx SCC non-smokers have significantly greater signature 5 mutations and are generally 
older compared with other HNSCC non-smokers. Comparing the number of signature 5 mutations 
in non-smokers (defined as lifelong non-smokers or historically reformed, >15 years), larynx had significantly 
more signature 5 mutations than either oral cavity or oropharynx (Fig. 3B). In contrast to smokers, non-smoking 
patients with larynx SCC (n = 11) were significantly older than non-smoking patients with oropharyngeal SCC 
(n = 14), while non-smoking patients with oral cavity SCC were approximately intermediate in age (n = 76) 
(Fig. 3C). No difference was seen with signature 1 mutations and major anatomical sub-site in non-smokers (data 
not shown).
Laryngeal SCC have significantly less Ki67 positive nuclei than oral cavity or oropharyngeal 
SCC. We next compared Ki-67 immuno-reactivity as a marker of tumor cell proliferation in similarly sized 
SCC excised from the larynx, oral cavity, and the oropharynx, from Thomas Jefferson University Hospital from 
2015–2018. Comparison of tumors 2–4 cm in size showed oral cavity and oropharyngeal tumors had significantly 
greater Ki67 cell positivity per tumor when compared with laryngeal tumors (Fig. 4 and Supplementary Table S1).
Discussion
Tobacco use is the principle risk factor for developing HNSCC and therefore our findings that tobacco associ-
ated mutations are conspicuously and significantly reduced in oral cavity and oropharynx SCC compared with 
larynx SCC presents a number of intriguing possibilities with regards to the direct effects of tobacco smoke on 
somatic mutations in HNSCC. It is important to note that we are not the first to identify a difference between 
Figure 3. Signature 5 mutations shows positive correlation with age in non-smokers and are enriched in larynx 
SCC non-smoking patients who are older than non-smoking patients with oropharynx SCC. (A) Graphs shows 
the number of signature 5 mutations (y-axis) plotted against the age (x-axis) of all smokers (left graph, n = 170) 
or non-smokers (right graph, n = 101) with HNSCC. Pearson Correlation r and p values given. (B) Box and 
Whisker plots show the number of signature 5 mutations identified in HNSCC of non-smokers stratified by 
major anatomical sub-site. (C) Box and Whisker plots showing age of patients with HNSCC stratified by major 
anatomical sub-site in smokers (left graph) and non-smokers) right graph). Signature 5 is derived from version 
2 of COSMIC mutational signatures, is of unknown etiology, and associated with age in certain cancers and 
somatic tissues. x = mean *p < 0.05.
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larynx and other sub-sites with regards to tobacco smoke mutation signatures29,30. However, these prior studies 
either used relative ratios of single base pair changes29, or compared COSMIC signatures not previously extracted 
from HNSCC datasets (https://cancer.sanger.ac.uk/signatures_v2/matrix.png) with exclusion of signature 530. 
We show here that the increased mutation burden in larynx SCC noted by others is a direct result of tobacco 
smoke-associated signature 4 mutation load (Fig. 1, Supplementary Figs. S2 and S5).
The observation that larynx SCC have significantly more signature 4 mutations than other major sub-sites of 
HNSCC indicates that larynx SCC are more susceptible to miss-replication after DNA adduct formation leading 
to mutation. We speculate that the reason for this could be due to a number of possible hypotheses or combina-
tions thereof. The first hypothesis is simply anatomical location; the larynx could be exposed to more tobacco 
smoke saturated mucous than other HNSCC sub-sites due to its proximity to trachea and upper lung airways. 
The second hypothesis is that the larynx harbor mutations in DNA repair genes which sensitizes this anatomical 
location to mutations from tobacco smoke. However, mutation analysis has not identified differences in somatic 
mutation of repair genes11–14 and CNA differences could well result from replication pressures associated with 
increased mutation burden. The third hypothesis for DNA adduct mutation susceptibility could be inherent dif-
ferences in keratinocytes which line the laryngeal cavity as this structure differs from others in the oral cavity 
with respect to developmental origin; the larynx emerges from the foregut endoderm while much of the oral 
Figure 4. Ki-67 immuno-reactivity is increased in oral cavity SCC and oropharynx SCC compared with larynx 
SCC. (A) Representative larynx SCC section incubated with anti-Ki = 67 antibodies and visualized using 
the Aperio platform. (B) Representative oral cavity SCC section incubated with anti-Ki = 67 antibodies and 
visualized using the Aperio platform. (C) Representative oropharynx SCC section incubated with anti-Ki = 67 
antibodies and visualized using the Aperio platform. Bar = 400 μM. (D) Graph shows % Ki-67 positive tumor 
cells quantified using Aperio ImageScope for 19 larynx SCC, 22 oral cavity SCC, and 18 oropharynx SCC. 
Bar shows mean +/− standard deviation with individual points shown as circles. Blue indicates P16 positive 
samples. P16 not assessed in 2 larynx SCC and 11 oral cavity SCC. **p < 0.01, ***p < 0.001.
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cavity emerges from the oral ectoderm31,32. Endoderm-derived keratinocytes may have differential DNA repair 
capabilities compared with ectodermal derived keratinocytes, regardless of somatic driver-gene mutations. This 
may also influence the number of signature 5 mutations which presumably arise through miss-replication of DNA 
during cell division. However, at the time of writing we were not aware of any literature addressing this possibility.
The last hypothesis is that steady state keratinocytes, regardless of anatomical location, do not differ in their 
ability to repair DNA adducts and the accumulation of signature 4 mutations is a factor of tumor growth over 
time. In this model, signature 4 mutations accumulate over time, and would predict that larynx SCC take longer 
to develop than those arising in the oral cavity or oropharynx.
Whilst the analysis presented in our study is descriptive in nature and we have not carried out experiments 
to test this model directly, there are aspects of our data and that of others which support our last hypothesis. 
Firstly, signature 5 mutations, associated with age in other SCC and also tobacco use, are increased in number 
in larynx SCC (Figs. 1 and 3) and whilst this could indicate a deficiency in DNA repair (as signature 5 mutations 
are associated with replication errors) the data fit with the notion of older tumors in the larynx and is supported 
by the observation that signature 5 mutations increase with cellular proliferation28. Furthermore, the prolifer-
ative index in larynx SCC was significantly less than size-matched oral cavity and oropharyngeal SCC (Fig. 4) 
which would support the idea that larynx SCC are slower growing and this would be a plausible explanation for 
increased exposure to mutagens and mutation burden. Our analysis of the age of non-smoking patients suggests 
that those with larynx SCC are older which could support this notion, however statistical significance was only 
seen compared with oropharynx SCC (Fig. 3C) and is likely confounded by HPV infection where patients are 
generally younger33. Unfortunately, the numbers of HPV positive tumors in the larynx and HPV negative tumors 
in oropharynx assessed in Fig. 4 are too small to determine the influence of HPV status on Ki67 proliferation 
index and we note conflicting results in the literature34,35 which together with our data advocate further interro-
gation of this issue.
One potential confounder to these observations that must be acknowledged is the similarity between sig-
nature 4 and signature 5. Whilst signature 5 is relatively evenly distributed (affecting all nucleotide mutation 
combinations relatively equally) it is the only other mutation signature found in HNSCC that has a substantial 
contribution of C > A nucleotide change (Supplementary Fig. S5B). Signature 4 is dominated by C > A transver-
sions but is also similar to signature 5 in that the rest of the nucleotide variations are also relatively evenly distrib-
uted, albeit at a lower proportion than C > A. Therefore the ability to distinguish between the two, especially in 
tumors with limited mutation numbers is challenging. Regardless of this, it is clear that those larynx SCC positive 
for signature 4 harbor the most mutations compared with all other HNSCC combinations and the observation 
that signature 4 mutation dominates larynx SCC is well supported (Fig. 1, Supplementary Figs. S2 and S3A,B, S5).
The data presented here and our proposed model of larynx SCC developing over longer periods of time cou-
pled with susceptibility to tobacco smoke mutations, are in keeping with a number of prior investigations and 
observations. Multi-region exome sequencing has shown that larynx SCC have greater heterogeneity compared 
with oral cavity SCC36 and it is conceivable that heterogeneity develops over time with an older tumor accumu-
lating multiple clonal mutations37. Epidemiological observations by Doll and colleagues demonstrate that risk of 
death in smokers who have given up at age 30 are similar to those individuals who have never smoked, and only 
every year after 30 that an individual smokes increases your risk38. These observations would also be congruent 
with mutations in either the upper aero-digestive tract or lungs occurring over time, as cells age and lose DNA 
repair efficiency.
Given that not all smokers develop cancer (only 24% of male smokers and 11% of female smokers die from 
lung cancer over their lifetime39), a greater understanding of the factors and mechanisms that identify those 
smokers who have higher cancer risk could lead to prevention or early detection approaches. Further work to test 
our model of DNA adduct mutation susceptibility in laryngeal keratinocytes may provide insight on this subject.
In summary, our data show that larynx SCC are more susceptible to mutations associated with tobacco prod-
uct DNA-adduct formation and suggest that SCC in the larynx take longer to progress compared with other 
HNSCC.
Materials and Methods
Mutation signature analysis. Our original, published analysis, used methodology from the Wellcome 
Trust Sanger Institute (WTSI) to extract signatures of mutation from exome sequencing of HNSCC samples27. 
Briefly, mutational signatures were extracted using 96 nonnegative components (singlebase somatic substitu-
tions and their immediate sequence context) and compared to the validated consensus mutational signatures in 
COSMIC, version 2 (https://cancer.sanger.ac.uk/cosmic/signatures_v2) to identify the set of COSMIC mutational 
signatures in TCGA data sets40. This analysis identified COSMIC signatures 1, 2, 4, 5, 7, 13, and 18. Here we 
repeated signature assignation using the program deconstructSigs41 focusing on TCGA single nucleotide varia-
tion for the initial data freeze of HNSCC samples14 downloaded from the National Cancer Institute GDC Data 
Portal (https://portal.gdc.cancer.gov/projects/TCGA-HNSC). Initially we included all signatures identified using 
the WTSI method and comparison of deconstructSigs (using normalization within the sample and a cutoff of 
0.01) with WTSI showed good concordance on results (Supplementary Fig. S6A,B) and analysis of anatomical 
sub-site and signature 4 and signature 5 presence were not different (Supplementary Fig. S6C,D c.f. Fig. 1B,C). A 
single sample from the lip showed a large contribution of signature 7 while other samples from a diverse range of 
non-sun exposed anatomical sub-sites showed much lower contribution of signature 7 (<40 percent in a given 
sample) regardless of method used (Supplementary Fig. S6B, lower panel). Because signature 7 is associated with 
UV exposure and not expected to be active in non-sun exposed sites, we repeated deconstructSigs analysis with 
exclusion of the single lip sample and signature 7. Since this study, V3 of COSMIC signatures have now been 
established42.
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Ki67 proliferation index. This retrospective study of archival, anonymized, diagnostic material was 
approved by the internal review board of Thomas Jefferson University and the need for written informed consent 
was waived by the same internal review board. All subsequent experiments were performed in accordance with 
relevant guidelines and regulations. Specimens of laryngeal, oral cavity and oropharyngeal SCC were retrospec-
tively searched for in the SCC Tumor Biorepository (Sidney Kimmel Cancer Center, Thomas Jefferson University, 
Philadelphia, PA) from 2015 to 2018. As this analysis is comparative, we took care to select specimens that were 
uniform regarding tumor size as dictated by the final pathology report. We randomly selected formalin-fixed, 
paraffin embedded blocks of 60 cases from different patients, with enough material for new sections, compro-
mising 19–22 specimens for each group. HPV positivity was previously determined on the basis of positive P16 
immuno-histochemistry. Of the three larynx samples that were positive for P16, one was subjected to HPV in 
situ hybridization for HPV16 and HPV18 and tested positive for HPV18. Of the 16 oropharynx samples that 
were positive for P16, 11 were subjected to HPV in situ hybridization for HPV16 and HPV18, and one tested 
positive for HPV18, eight tested positive for HPV16, and 2 were negative. All of the selected cases were sectioned 
and stained for Ki67. One case was excluded from the oropharyngeal SCC group due to inappropriate immuno-
histochemical reaction for Ki67. At the end, the laryngeal SCC group consisted of 19 samples (n = 19), the oral 
cavity group consisted of 22 samples (n = 22), and the oropharyngeal SCC group consisted of 18 (n = 18). Three 
representative fields in each group were picked at 400x magnification (0.2 mm2/field) with the operator being 
blinded to tumor sites. All positive and negative nuclei of neoplastic cells were analyzed with the aid of Aperio 
ImageScope (Leica Biosystems Inc. Buffalo Grove, IL). The percentage of positive nuclei per total recorded nuclei 
was then noted. Supplementary Table S1 provides details of each of the samples included in Fig. 4.
Statistical analysis. For comparison of smoking status between larynx, oral cavity and oropharynx we 
applied the proportional adjacent-categories-ratio model using the R package VGAM43. This model shows that 
compared to larynx, both oral cavity and oropharynx patient groups have lower probability of more severe smok-
ing status (adjacent-categories-ratio of 0.505 and 0.491, respectively, both p < 0.001), while there is no significant 
difference between the oral cavity and oropharynx group. Remaining statistical analysis was performed using 
Prism 8 (GraphPad Software, La Jolla, CA). For comparison of mutation numbers and mutations signatures the 
Mann-Whitney U test was used. Pearson correlation was used to analyze relationships between age and mutation 
signature numbers and unpaired t-test was used to analyze Ki-67 proliferation index between separate tissue 
group immuno-histochemistry.
Data availability
All data are available on request.
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